Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) EBIT Margin (2024 - 2025)

Kura Oncology (KURA) has disclosed EBIT Margin for 2 consecutive years, with 464.82% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 463257.0% to 464.82% in Q4 2025 year-over-year; TTM through Dec 2025 was 772.86%, a 1199238.0% decrease, with the full-year FY2025 number at 449.94%, down 9140.0% from a year prior.
  • EBIT Margin was 464.82% for Q4 2025 at Kura Oncology, down from 385.53% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 16937.17% in Q1 2025 to a low of 464.82% in Q4 2025.